Draft:Philipp Haas
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Coverage is WP:ROUTINE or the equivalent of WP:ORGTRIV. Nothing compelling here to establish notability. Also, please consider a read of WP:BOSS Sulfurboy (talk) 04:31, 25 July 2026 (UTC)
- Comment: In accordance with the Wikimedia Foundation's Terms of Use, I am an employee of DEVA Holding and have a professional connection to the subject of this draft. Emre888 (talk) 12:12, 24 July 2026 (UTC)
Philipp Haas | |
|---|---|
 Philipp Haas | |
| Occupation | Business executive |
| Known for | Chairman and CEO of DEVA Holding |
Philipp Daniel Haas is a business executive working in the investment and pharmaceutical sectors. He is the chairman and chief executive officer of DEVA Holding and the chairman of EastPharma Ltd.[1]
Education and career
[edit]Haas completed a master's degree in business administration at the University of St. Gallen in Switzerland, specialising in banking. He began his career in investment advisory and corporate management. During the 1990s, he served on the boards of Rogan Brewery in Ukraine and Net Holding in Turkey on behalf of institutional investors. He also advised on pharmaceutical investment projects, including work related to Slovakopharma, which later operated under the Zentiva name.[1]
Following EastPharma's acquisition of a majority stake in DEVA Holding in 2006, Haas joined the company's management. In reports published in 2008, he was identified as chairman of DEVA Holding and commented on the growth objectives, public-listing considerations, manufacturing investments and Roche cooperation of EastPharma and DEVA Holding.[2][3]
A Reuters report published in 2010 included Haas's comments on DEVA Holding's sales performance and investments in new manufacturing facilities.[4]
In subsequent years, Haas gave interviews to international pharmaceutical industry publications, including PharmaBoardroom and Global Business Reports, about DEVA Holding's international operations, exports, research and development activities and manufacturing investments. In these interviews, he discussed the company's growth strategy, production capacity and objectives in international markets, particularly Europe and the United States.[5][6][7]
In a 2017 interview published by the international pharmaceutical trade publication Pharma Horizon, Haas discussed DEVA Holding's restructuring following the 2006 change of ownership, the modernisation of its manufacturing facilities, production growth and expansion into regulated international markets.[8]
In a 2019 profile and interview, Fortune Türkiye covered Haas's role in DEVA Holding's localisation, export, research and development and value-added manufacturing strategy.[9] Anadolu Agency had previously reported his comments on the company's financial performance, European Good Manufacturing Practice approval and manufacturing investments in 2012.[10]
In February 2020, the English-language business publication The Turkish Perspective published an interview with Haas covering DEVA Holding's investment activities in Turkey, export strategy, international operations and biotechnology investments.[11]
Haas was also quoted in Global Business Reports' editorial coverage of the Turkish pharmaceutical industry. In 2020, he discussed DEVA Holding's export-led growth, the need for a cautious approach to biopharmaceutical investment, the contraction in pharmaceutical activity during the COVID-19 pandemic and pressures on active pharmaceutical ingredient supply chains.[12][13][14]
In 2024, Haas was interviewed by the Mexican healthcare publication Saludiario during a visit to Mexico. He discussed the country's attractiveness for pharmaceutical investment, the conditions required for competitiveness in the industry and Devatis's plans for the Mexican market.[15]
In a sponsored special publication distributed with the Swiss edition of Medical Tribune in 2025, Haas discussed his earlier career in finance, the acquisition and modernisation of DEVA Holding, Devatis's international expansion and the company's vertically integrated manufacturing and supply model.[16]
Haas's views on the Turkish pharmaceutical market, research and development investment, exports and pharmaceutical licensing procedures have also appeared in healthcare and industry publications.[17][18]
Haas continues to hold board and management positions at DEVA Holding, EastPharma and several affiliated companies.[1]
References
[edit]- ^ a b c "Board of Directors". DEVA Holding. Retrieved 22 July 2026.
- ^ "DEVA'nın ana ortağı İMKB'ye kote ilk yabancı şirket olacak". Dünya (in Turkish). 18 March 2008. Retrieved 22 July 2026.
- ^ "DEVA Holding, 16 Roche ürünü için son imzayı attı". Habertürk (in Turkish). 2 July 2008. Retrieved 22 July 2026.
- ^ "DEVA expects full-year results to match first-half growth". Investment Office of the Presidency of the Republic of Türkiye. Reuters. 2 September 2010. Retrieved 22 July 2026.
- ^ "Philipp Haas – Chairman & CEO, DEVA, Turkey". PharmaBoardroom. 29 October 2018. Retrieved 24 July 2026.
- ^ "Philipp Haas". Global Business Reports. January 2020. Retrieved 24 July 2026.
- ^ "Philipp Haas – Chairman of the Board and CEO, DEVA". PharmaBoardroom. 9 June 2021. Retrieved 24 July 2026.
- ^ "Philipp Haas – Chairman of the Board and CEO of DEVA". Pharma Horizon. TKS. 2017. Retrieved 24 July 2026.
- ^ "Antibiyotikle Başlayan Uzun Mesafe Koşusu". Fortune Türkiye (in Turkish). 19 July 2019. Retrieved 24 July 2026.
- ^ "Deva Holding'in ilk 9 aydaki net karı 26,9 milyon lira oldu". Anadolu Agency (in Turkish). 12 November 2012. Retrieved 24 July 2026.
- ^ "Interview: DEVA CEO Philipp Haas" (PDF). The Turkish Perspective. No. 79. Turkish Exporters Assembly. February 2020. pp. 52–54. Retrieved 24 July 2026.
- ^ "Export Markets: A Tale of Two Continents". Global Business Reports. March 2020. Retrieved 24 July 2026.
- ^ "Turkey's Nascent Biopharma Sector: The Transition to Large Molecules". Global Business Reports. May 2020. Retrieved 24 July 2026.
- ^ "Impact of COVID-19 in Turkey". Global Business Reports. May 2020. Retrieved 24 July 2026.
- ^ Rodrigo Rojas (28 October 2024). "ENTREVISTA: ¿Por qué México es un mercado atractivo para Devatis?". Saludiario (in Spanish). Retrieved 24 July 2026.
- ^ "Eine junge Firma mit klarer Ausrichtung" (PDF). Medical Tribune (in German). No. 51–52/2025. 2025. Retrieved 24 July 2026.
- ^ "DEVA CEO'su: Türk piyasasına en iyi kalitedeki ürünleri sunuyoruz". MediMagazin (in Turkish). 12 November 2012. Retrieved 24 July 2026.
- ^ "Philipp Haas: İlaçta ruhsat işlemleri hızlanmalı". Global Sanayici (in Turkish). Retrieved 24 July 2026.
- provide significant coverage: discuss the person in detail, not brief mentions or interviews lacking independent analysis;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the person, such as interviews, press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.